News

IQVIA Holdings Inc. Reports Third-Quarter 2026 Revenue of $4,428 million and Raises Full-Year Guidance

Fintel·10:12IQV

IQVIA Holdings Q3 Earnings Beat Estimates, Revenues Increase 8% Y/Y

IQV's Q3'26 earnings beat estimates as revenues rise 8% y/y, led by strong clinical demand, robust R&D bookings and improved execution, prompting a view hike.

Yahoo·09:42IQV

IQVIA Holdings Inc. (IQV) Q3 2026 Earnings Call Transcript

IQVIA Holdings Inc. (IQV) Q3 2026 Earnings Call October 27, 2026 9:00 AM EDTCompany ParticipantsKerri Joseph - Senior Vice President of Investor...

SeekingAlpha·08:49IQV

IQVIA’s (NYSE:IQV) Q3 2026: beats on revenue

Clinical research company IQVIA (NYSE: IQV) reported Q3 2026 results exceeding the market’s revenue expectations, with revenue up 8% year on year to $4.43 billion. The company expects the full year’s revenue to be around $17.43 billion, close to analysts’ consensus estimates. Its non-GAAP profit of $3.34 per share was 2% above analysts’ consensus estimates.

Yahoo·07:58IQV

IQVIA Holdings Inc. 2026 Q3 - Results - Earnings Call Presentation

IQVIA (IQV) Q3 earnings report preview: what to look for

Clinical research company IQVIA (NYSE: IQV) will be reporting results this Tuesday before market open. Here’s what to expect.

Yahoo·06:06IQV

Locking in Gains: Portfolio Discipline Triggers IQVIA Holding (IQV) Trim After Q2 Beat

Broyhill Asset Management, a Charlotte-based firm, issued its third-quarter 2026 investor letter. The letter can be downloaded here. The Broyhill Equity Composite decreased by 0.3% in Q3, underperforming the MSCI All Country World Index, which gained 1.7%. For the first nine months of the year, the Composite returned 1.9%, compared to 13.4% for the Index. The […]

Yahoo·12:20IQV

From Headwinds to Full Valuation: The Disciplined Exit of IQVIA Holdings (IQV)

Investment management company Vulcan Value Partners recently released its third-quarter 2026 investor letter. The letter can be downloaded here. The portfolio reported a strong quarter, with all strategies except Small Cap reporting positive absolute results, with Small Cap down about 1%. In the quarter, the Large Cap Composite (Net) returned 7.4%, the Small Cap Composite (Net) returned […]

Yahoo·11:44IQV

IQVIA Gears Up to Post Q3 Earnings: Here's What Investors Should Know

IQV is poised for y/y revenue and earnings growth in Q3, driven by stronger clinical research demand, solid bookings, AI adoption and operational efficiencies.

Yahoo·08:58IQV

Josh Brown's 'Best Stocks in the Market:' IQVIA

Josh Brown, CEO of Ritholtz Wealth Management, joins CNBC's 'Halftime Report' to spotlight IQVIA in his 'Best Stocks in the Market.'

CNBC·08:41IQV

IQVIA Holdings (IQV) Earnings Expected to Grow: Should You Buy?

IQVIA (IQV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo·09:00IQV

IQVIA: R&D Bookings Are Reaccelerating, But The Valuation Now Requires Execution

IQVIA (IQV) earns a Buy rating on strong Q2 results and R&D bookings recovery. See growth drivers, AI upside, key risks, and $285–$305 target.

SeekingAlpha·07:21IQV

IQVIA HOLDINGS INC (NYSE:IQV) Sets Up for Breakout With Strong Technical Ratings

IQVIA (IQV) earns 9/10 technical and setup ratings, consolidating near 52-week highs. See breakout entry, support, resistance, and key risks.

ChartMill·05:00IQV

IQVIA: A $34.2 Billion Backlog Does Not Guarantee Faster Earnings Growth

IQVIA Holdings (IQV) reported robust Q2 2026 results, with 8.7% revenue growth and a 19% increase in Research & Development Solutions bookings.

SeekingAlpha·04:06IQV

IQVIA Holdings (IQV) Gains as Improving Demand Environment and High Win Rates

Harris Oakmark recently released its third-quarter 2026 investor letter for its “Oakmark Global Fund”. The letter can be downloaded here. The Fund (Investor Class) returned 1.68% for the quarter, slightly trailing the MSCI World Index’s 1.88% return. Key performance contributors included information technology and financials, while consumer discretionary and industrials detracted. Regional allocations were predominantly 50.6% […]

Yahoo·11:05IQV

Stifel Maintains Buy on IQVIA Holdings, Raises Price Target to $303

Stifel analyst Shlomo Rosenbaum maintains IQVIA Holdings (NYSE:IQV) with a Buy and raises the price target from $276 to $303.

Benzinga·03:44IQV

IQVIA Selects Veeva Clinical Operations Applications

IQVIA (NYSE: IQV) and Veeva Systems (NYSE: VEEV) today announced an expansion of their partnership with the selection of Veeva CTMS, eTMF, Study Startup, and Site Connect as enterprise standard applications that will be used across IQVIA clinical development studies. This extends the previously announced EDC partnership.

Yahoo·07:03IQV

IQVIA Expands Partnership Veeva Systems On Enterprise Standard Applications That Will Be Used Across IQVIA Clinical Development Studies

IQVIA (NYSE:IQV) and Veeva Systems (NYSE:VEEV) today announced an expansion of their partnership with the selection of Veeva CTMS, eTMF, Study Startup, and Site Connect as enterprise standard applications that will be

Benzinga·03:15IQV

IQVIA Holdings’ Quarterly Earnings Preview: What You Need to Know

IQVIA Holdings is all set to post its third-quarter earnings later this month and analysts expect a high-single-digit boost in its EPS.

Yahoo·08:27IQV

IQVIA Launches IQVIA Life Science Models to Help Life Sciences Companies Predict Clinical Trial Outcomes

RESEARCH TRIANGLE PARK, N.C., October 07, 2026--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today at TechIQ 2026 introduced IQVIA Life Science ModelsTM to help predict clinical trial outcomes.

Yahoo·17:09IQV

Extensive Database & Solid Bookings Benefit IQVIA Amid Low Liquidity

IQV's vast healthcare database, AI-enabled capabilities and strong R&DS bookings support growth, while low liquidity and $14.1B net debt remain in focus.

Yahoo·10:28IQV

'HHS launches project to speed up clinical trials' - Axios

https://www.axios.com/2026/09/30/hhs-clinical-trials-redesign

Benzinga·11:17

UBS Reinstates Buy on IQVIA Holdings, Announces $345 Price Target

UBS analyst Kevin Caliendo reinstates IQVIA Holdings (NYSE:IQV) with a Buy and announces $345 price target.

Benzinga·04:19IQV

IQVIA to Announce Third-Quarter 2026 Results on October 27, 2026

RESEARCH TRIANGLE PARK, N.C., September 29, 2026--IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, will announce its third-quarter 2026 financial results before the market opens on Tuesday, October 27, 2026. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time that same day. The earnings release and accompany

Yahoo·16:15IQV

RBC Capital Maintains Outperform on IQVIA Holdings, Raises Price Target to $319

RBC Capital analyst Ryan Halsted maintains IQVIA Holdings (NYSE:IQV) with a Outperform and raises the price target from $247 to $319.

Benzinga·04:33IQV

Truist Securities Reiterates Buy on IQVIA Holdings, Raises Price Target to $329

Truist Securities analyst Jailendra Singh reiterates IQVIA Holdings (NYSE:IQV) with a Buy and raises the price target from $300 to $329.

Benzinga·07:13IQV

Can Doximity Keep Shrinking Its Share Count Through Its AI Investment Year?

Doximity (DOCS), which calls itself the leading digital platform for U.S. medical professionals, has seen its stock fall steeply over the past year. Even after a rise over the past three months, the shares sit about 65% below their 52-week high. Management continued its repurchase program, allocating approximately $401 million over the latest twelve months. The test is whether it can keep that up through what it calls its AI investment year.

Yahoo·09:25

IQVIA (NYSE:IQV) Nears Breakout With 10/10 Technical Strength and 9/10 Setup

IQVIA stock shows 10/10 technical strength and 9/10 setup quality, pointing to a controlled breakout base with a defined entry, exit, and risk.

ChartMill·07:11IQV

IQVIA Holdings (IQV) Prices $2b Notes, Does The Stock Look Fairly Valued?

IQVIA Holdings (IQV) has just priced a US$2b senior notes offering due 2034, a sizable refinancing move that reshapes its debt stack and gives investors fresh information on the company’s funding costs and capital structure. Over the past year IQVIA Holdings has delivered a 42.3% total shareholder return, with the share price up 58.8% over the last 90 days and 6.9% over the past month. The recent 1.1% daily pullback to US$266.42 therefore looks more like a pause after strong momentum than a...

Yahoo·19:08IQV

IQVIA (IQV) Stock Could Be Undervalued After Its 42% Run

IQVIA Holdings has delivered a strong share-price run recently, which naturally puts more focus on whether the cash it is expected to generate can support the current valuation. With the stock now trading in a different zone to where it sat a year ago, the question is how that move lines up with its underlying cash flows. The share price is up 42.3% over the past year, which puts real pressure on the cash flow story to justify where IQVIA sits today. The company has priced a US$2b senior...

Yahoo·17:13

Morgan Stanley Maintains Equal-Weight on IQVIA Holdings, Raises Price Target to $270

Morgan Stanley analyst Kallum Titchmarsh maintains IQVIA Holdings (NYSE:IQV) with a Equal-Weight and raises the price target from $240 to $270.

Benzinga·07:52IQV

A Strong Rebound Case of IQVIA Holdings (IQV)

Broyhill Asset Management, a Charlotte-based firm, issued its second-quarter 2026 investor letter, which is available for download here. The Broyhill Equity Composite gained 8.8% in Q2, trailing the MSCI All Country World Index’s 15.1% and the MSCI ACWI Value Index’s 10.8%. For the first half, the Composite returned 2.3%, versus 11.5% for the Index. The […]

Yahoo·09:57IQV

Why Is NeuroPace (NPCE) Down 0.4% Since Last Earnings Report?

NeuroPace (NPCE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Yahoo·11:30

IQVIA Holdings Stock: Is IQV Outperforming the Health Care Sector?

IQVIA Holdings has outperformed the Health Care sector over the past year, and analysts are highly optimistic about the stock’s prospects.

Yahoo·09:56IQV

IQVIA's Predictive Clinical Development Provides Sponsors With Significant Efficiencies to Get Treatments to Market Faster

RESEARCH TRIANGLE PARK, N.C., September 03, 2026--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence, today announced IQVIA Predictive Clinical Development, an AI-powered approach designed to help life sciences sponsors reduce avoidable delays and bring new therapies to patients up to two years faster.

Yahoo·17:15IQV

VEEV Raises FY27 Outlook as Vault CRM and AI Momentum Accelerate Fast

Veeva raises its fiscal 2027 outlook as Vault CRM adoption, R&D growth and Falcon AI momentum support expanding revenue and profitability.

Yahoo·14:10

Why Is TransMedics (TMDX) Up 10.2% Since Last Earnings Report?

TransMedics (TMDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Yahoo·11:30

This Payroll Software Company Bought Back 20% of Its Shares and the Stock Has Nearly Doubled Since April

While most software companies were retreating, Paycom made an aggressive and unconventional bet on itself, and the market delivered a verdict that caught even seasoned analysts off guard.

Yahoo·15:42

Q2 Earnings Roundup: IQVIA (NYSE:IQV) And The Rest Of The Drug Development Inputs & Services Segment

As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the drug development inputs & services industry, including IQVIA (NYSE:IQV) and its peers.

Yahoo·17:52IQV

How Strong Q2 Beat And Raised 2026 Guidance At IQVIA Holdings (IQV) Has Changed Its Investment Story

Earlier in the current quarter, IQVIA Holdings reported second-quarter results that topped earnings expectations, with adjusted earnings rising 12.1% year over year and revenue increasing 8.7%, prompting management to raise its 2026 revenue, adjusted EBITDA and adjusted diluted earnings guidance. This upgrade was backed by broad-based demand, strong bookings and contributions from acquisitions, all of which reinforced management’s view that business momentum can be sustained into 2027. With...

Yahoo·05:21IQV

Amgen Stock Signals Its Confidence. The Market Agrees.

The real bet is on what lies beyond this year's performance: a pipeline that could change everything.

Yahoo·21:19

IQVIA Wins Multiple Industry Awards for AI and Technology Innovation Across Life Sciences and Healthcare

RESEARCH TRIANGLE PARK, N.C., August 27, 2026--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today announced it received recognition this year from multiple independent industry awards programs for its use of AI to help healthcare and life sciences organizations improve decisions, strengthen regulated workflows, protect patient privacy and optimize clinical trial execution

Yahoo·17:15IQV

Why Is IQVIA (IQV) Up 5.6% Since Last Earnings Report?

IQVIA (IQV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Yahoo·12:30IQV

Here's Why You Should Retain IQVIA Stock in Your Portfolio Now

IQV shares rise 21.7% in a month as data assets, AI-enabled technology and strong cash flow support growth despite liquidity and pricing risks.

Yahoo·12:17IQV

2 Large-Cap Stocks with Exciting Potential and 1 That Underwhelm

Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new areas for growth is much harder than for smaller, more agile players.

Yahoo·05:22

CRL Jumps 33.3% in the Past Month: Can This Strong Rally Keep Running?

Charles River's 33.3% monthly surge faces a higher bar as stronger bookings and guidance meet margin pressure and a premium valuation.

Yahoo·11:37

IQVIA Holdings Stock Outlook: Is Wall Street Bullish or Bearish?

Despite already outperforming the broader market over the past year, IQVIA continues to enjoy strong backing from Wall Street, with analysts remaining highly optimistic about the stock’s future prospects.

Yahoo·08:40IQV

IQVIA's AI-Enabled Clinical Decision Support Tool Wins 2026 AI Breakthrough Award for Predictive Modeling Solution of the Year

RESEARCH TRIANGLE PARK, N.C., August 20, 2026--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today announced that its AI-enabled Clinical Decision Support Tool, developed in collaboration with Breakthrough T1D, has won the 2026 AI Breakthrough Award for Predictive Modeling Solution of the Year.

Yahoo·17:15IQV

IQVIA Ranked No. 1 Pharmaceutical Technology Provider by Everest Group

RESEARCH TRIANGLE PARK, N.C., August 17, 2026--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today announced that it has been ranked No. 1 in Everest Group’s "Top 50™ Pharmaceutical Technology Providers" report for 2026.

Yahoo·17:15IQV

This Healthcare Services Stock Has 37% Upside

Well-known pharmaceutical companies such as Merck and Pfizer typically manage this complex process in house. Medpace Holdings which targets oncology, metabolic, cardiology, central nervous system, and anti-infective therapies, raised its 2026 revenue guidance on July’s second-quarter conference call to a midpoint of $2.85 billion, corresponding to a year-over-year increase of 13%. Three months later, Medpace is in the pink: On the heels of second-quarter earnings, the stock is up 14%.

Yahoo·08:01

Amgen Stock And The Price Of A Promise

Management raised its full-year forecast, but the market seems to be asking for more than a higher target.

Yahoo·15:17

IQV Stock Gains 42% in 3 Months: Here's What You Should Know

IQVIA shares jump 41.5% in three months as record R&DS bookings, a solid backlog, raised 2026 guidance and share buybacks support sentiment.

Yahoo·09:09IQV

Rotation Away From Tech Lifts Moat Index In July

The Moat Index gained 3.96%, outperforming the S&P 500 as its lower mega-cap technology exposure and financials tilt paid off.

SeekingAlpha·03:13

How Investors Are Reacting To IQVIA Holdings (IQV) Cardiac Gene Therapy Push And Higher 2026 Revenue Outlook

In late July and early August 2026, IQVIA Holdings and Medera announced a collaboration pairing IQVIA’s global clinical and commercialization infrastructure with Medera’s Sardocor and Novoheart cardiac gene therapy and human-based drug discovery platforms, alongside IQVIA’s second-quarter results, raised full-year 2026 revenue guidance to between US$17.28 billion and US$17.48 billion, and continued share repurchases. The partnership’s focus on AAV-based cardiac gene therapies and Novoheart’s...

Yahoo·11:11IQV

IQVIA, Medera Partner to Accelerate Development of Cardiac Gene Therapies

By Exec Edge Editorial Staff IQVIA (NYSE: IQV) and clinical-stage biopharmaceutical company Medera Inc. announced a strategic collaboration aimed at accelerating the development of cardiac gene therapies and human-based drug discovery platforms. Under the partnership, Medera’s Sardocor unit will use IQVIA’s clinical trial, regulatory and commercialization capabilities to advance FDA-cleared, first-in-human gene therapy programs targeting […] The post IQVIA, Medera Partner to Accelerate Developme

Yahoo·12:30IQV

Is ICON a Buy as Valuation Improves but Earnings Risks Still Persist?

ICLR's discounted valuation and $23.4B backlog support upside potential, but falling estimates, weaker margins and execution risks argue for patience.

Yahoo·11:29